Compare STTK & PLBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STTK | PLBC |
|---|---|---|
| Founded | 2016 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 275.9M | 320.9M |
| IPO Year | 2020 | 2002 |
| Metric | STTK | PLBC |
|---|---|---|
| Price | $6.00 | $47.54 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 2 |
| Target Price | $7.60 | ★ $55.50 |
| AVG Volume (30 Days) | ★ 589.2K | 33.1K |
| Earning Date | 01-01-0001 | 04-22-2026 |
| Dividend Yield | N/A | ★ 2.71% |
| EPS Growth | ★ 53.02 | N/A |
| EPS | N/A | ★ 2.94 |
| Revenue | ★ $1,000,000.00 | N/A |
| Revenue This Year | N/A | $25.59 |
| Revenue Next Year | N/A | $5.15 |
| P/E Ratio | ★ N/A | $16.57 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.69 | $38.71 |
| 52 Week High | $6.27 | $54.58 |
| Indicator | STTK | PLBC |
|---|---|---|
| Relative Strength Index (RSI) | 71.72 | 32.82 |
| Support Level | $1.85 | $40.95 |
| Resistance Level | N/A | $49.24 |
| Average True Range (ATR) | 0.42 | 1.39 |
| MACD | 0.09 | -0.40 |
| Stochastic Oscillator | 89.41 | 7.02 |
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
Plumas Bancorp provides various banking products and services in Northeastern California and Northwestern Nevada. It provides various deposit products such as checking, interest-bearing checking, business sweep, public funds sweep, savings, time deposit, and retirement accounts. The bank's loan portfolio consists of commercial real estate loans; commercial and industrial loans; consumer loans; agricultural loans; residential real estate loans, and construction and land development loans. The bank generates revenue from loans and investment securities in its portfolio and, to a lesser extent, service fees.